Ri Xiang Kong
Direttore Tecnico/Scientifico/R&S presso Beijing Biostar Pharmaceuticals Co. Ltd.
Profilo
Ri Xiang Kong is a Member-Supervisory Board at Beijing Biostar Pharmaceuticals Co. Ltd.
since 2003.
He graduated from Tianjin University of Science & Technology in 2002.
Posizioni attive di Ri Xiang Kong
| Società | Posizione | Inizio |
|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Direttore Tecnico/Scientifico/R&S | 01/12/2018 |
Formazione di Ri Xiang Kong
| Tianjin University of Science & Technology | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
- Borsa valori
- Insiders
- Ri Xiang Kong
